---
title: "Vir Biotechnology, Inc. (VIR.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/VIR.US.md"
symbol: "VIR.US"
name: "Vir Biotechnology, Inc."
industry: "Biotechnology"
datetime: "2026-04-16T11:43:52.521Z"
locales:
  - [en](https://longbridge.com/en/quote/VIR.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/VIR.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/VIR.US.md)
---

# Vir Biotechnology, Inc. (VIR.US)

## Company Overview

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company’s preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.vir.bio](https://www.vir.bio) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-16T04:30:16.000Z

**Overall: D (0.67)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 245 / 393 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -7.61% |  |
| Net Profit YoY | 16.09% |  |
| P/B Ratio | 2.18 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1671627191.70 |  |
| Revenue | 68556000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -45.73% | E |
| Profit Margin | -638.87% | E |
| Gross Margin | -548.38% | E |
| Revenue YoY | -7.61% | D |
| Net Profit YoY | 16.09% | B |
| Total Assets YoY | -28.31% | E |
| Net Assets YoY | -33.48% | E |
| Cash Flow Margin | 89.45% | C |
| OCF YoY | -7.61% | D |
| Turnover | 0.06 | E |
| Gearing Ratio | 23.69% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Vir Biotechnology, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-7.61%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "16.09%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.18",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1671627191.70",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "68556000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-45.73%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-638.87%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-548.38%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-7.61%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "16.09%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-28.31%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-33.48%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "89.45%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-7.61%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.06",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "23.69%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.82 | 330/393 | - | - | - |
| PB | 2.18 | 193/393 | 1.31 | 0.85 | 0.69 |
| PS (TTM) | 24.38 | 208/393 | 49.51 | 36.56 | 23.43 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | Vertex Pharma (VRTX.US) | A | B | C | B | C | B |
| 05 | Regeneron Pharma (REGN.US) | A | C | C | B | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-11T04:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 7 | 70% |
| Overweight | 3 | 30% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 10.46 |
| Highest Target | 30.00 |
| Lowest Target | 17.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/VIR.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/VIR.US/norm.md)
- [Related News](https://longbridge.com/en/quote/VIR.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/VIR.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**